These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 11723233)
41. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Shen HW; Wu C; Jiang XL; Yu AM Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139 [TBL] [Abstract][Full Text] [Related]
42. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. He ZX; Chen XW; Zhou ZW; Zhou SF Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Dalén P; Dahl M; Andersson K; Bertilsson L Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914 [TBL] [Abstract][Full Text] [Related]
44. Genetic evidence that HNF-1alpha-dependent transcriptional control of HNF-4alpha is essential for human pancreatic beta cell function. Hansen SK; Párrizas M; Jensen ML; Pruhova S; Ek J; Boj SF; Johansen A; Maestro MA; Rivera F; Eiberg H; Andel M; Lebl J; Pedersen O; Ferrer J; Hansen T J Clin Invest; 2002 Sep; 110(6):827-33. PubMed ID: 12235114 [TBL] [Abstract][Full Text] [Related]
45. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768 [TBL] [Abstract][Full Text] [Related]
46. Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice. Pan X; Jeong H Mol Pharmacol; 2015 Jul; 88(1):106-12. PubMed ID: 25943116 [TBL] [Abstract][Full Text] [Related]
47. Cytokine regulation of human sterol 12alpha-hydroxylase (CYP8B1) gene. Jahan A; Chiang JY Am J Physiol Gastrointest Liver Physiol; 2005 Apr; 288(4):G685-95. PubMed ID: 15550563 [TBL] [Abstract][Full Text] [Related]
48. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380 [TBL] [Abstract][Full Text] [Related]
49. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424 [TBL] [Abstract][Full Text] [Related]
50. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene]. Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918 [TBL] [Abstract][Full Text] [Related]
51. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Ishii M; Xu BQ; Ding LR; Fischer NE; Inaba T Toxicol Lett; 2001 Mar; 119(3):219-25. PubMed ID: 11246175 [TBL] [Abstract][Full Text] [Related]
52. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461 [TBL] [Abstract][Full Text] [Related]
53. Identification of retinoic acid-responsive elements on the HNF1alpha and HNF4alpha genes. Qian A; Cai Y; Magee TR; Wan YJ Biochem Biophys Res Commun; 2000 Oct; 276(3):837-42. PubMed ID: 11027556 [TBL] [Abstract][Full Text] [Related]
54. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523 [TBL] [Abstract][Full Text] [Related]
55. The G115S mutation associated with maturity-onset diabetes of the young impairs hepatocyte nuclear factor 4alpha activities and introduces a PKA phosphorylation site in its DNA-binding domain. Oxombre B; Kouach M; Moerman E; Formstecher P; Laine B Biochem J; 2004 Nov; 383(Pt. 3):573-80. PubMed ID: 15233628 [TBL] [Abstract][Full Text] [Related]